Letrozole
- PDF / 276,506 Bytes
- 18 Pages / 504.57 x 720 pts Page_size
- 72 Downloads / 156 Views
ADIS DRUG EVALUATION
© 2004 Adis Data Information BV. All rights reserved.
Letrozole A Review of its Use in Postmenopausal Women with Breast Cancer Dene Simpson, Monique P. Curran and Caroline M. Perry Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: L. Bordeleau, Medical Oncology, University of Toronto, Toronto, Ontario, Canada; H.J. Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; S.E. Come, Breast Cancer Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; G.M. Higa, School of Pharmacy, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, USA; K.I. Pritchard, Clinical Trials and Epidemiology, Toronto-Sunnybrook Regional Cancer Centre, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; C. Zielinski, Division of Oncology, Department of Medicine I, University Hospital of Vienna, Vienna, Austria. Data Selection Sources: Medical literature published in any language since 1980 on letrozole, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘letrozole’ or ‘CGS-20267’ and ‘breast cancer’ or breast neoplasms’. EMBASE search terms were ‘letrozole’ and ‘breast cancer’. AdisBase search terms were ‘letrozole’ or ‘CGS-20267’ and ‘breast-cancer’. Searches were last updated 27 April 2004. Selection: Studies in patients with breast cancer who received letrozole. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Letrozole, breast cancer, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1214 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1216 2. Overview of Pharmacological Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1217 2.1 Pharmacodynamic Profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1217 2.2 Pharmacokinetic Profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1217 3. Therapeutic Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
